Kreckler Laura M, Wan Tina C, Ge Zhi-Dong, Auchampach John A
Department of Pharmacology, Medical College of Wisconsin, Milwaukee, 53226, USA.
J Pharmacol Exp Ther. 2006 Apr;317(1):172-80. doi: 10.1124/jpet.105.096016. Epub 2005 Dec 9.
Adenosine is elaborated in injured tissues where it suppresses inflammatory responses of essentially all immune cells, including production of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha). Most of the anti-inflammatory actions of adenosine have been attributed to signaling through the A(2A) adenosine receptor (A(2A)AR). Previously, however, it has been shown that the A(3)AR agonist N(6)-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide (IB-MECA) potently inhibited TNF-alpha release from macrophages obtained from A(2A)AR "knockout" (A(2A)KO) mice, suggesting that the A(3)AR may also regulate cytokine expression. Here, we confirmed that the A(2A)AR is the primary AR subtype that suppresses TNF-alpha release from thioglycollate-elicited mouse peritoneal macrophages induced by both Toll-like receptor-dependent (TLR) and TLR-independent stimuli, but we determined that the A(2B)AR rather than the A(3)AR mediates the non-A(2A)AR actions of adenosine since 1) the ability of IB-MECA to inhibit TNF-alpha release was not altered in macrophages isolated from A(3)KO mice, and 2) the A(2B)AR antagonist 1,3-dipropyl-8-[4-[((4-cyanophenyl)carbamoylmethyl)oxy]phenyl]xanthine (MRS 1754) blocked the ability of the nonselective AR agonist adenosine-5'-N-ethylcarboxamide (NECA) to inhibit TNF-alpha release from macrophages isolated from A(2A)KO mice. Although A(2B)ARs seem capable of inhibiting TNF-alpha release, the A(2A)AR plays a dominant suppressive role since MRS 1754 did not block the ability of NECA to inhibit TNF-alpha release from macrophages isolated from wild-type (WT) mice. Furthermore, the potency and efficacy of adenosine to inhibit TNF-alpha release from WT macrophages were not influenced by blocking A(2B)ARs with MRS 1754. The data indicate that adenosine suppresses TNF-alpha release from macrophages primarily via A(2A)ARs, although the A(2B)AR seems to play an underlying inhibitory role that may contribute to the anti-inflammatory actions of adenosine under select circumstances.
腺苷在受损组织中产生,它能抑制基本上所有免疫细胞的炎症反应,包括肿瘤坏死因子-α(TNF-α)等促炎细胞因子的产生。腺苷的大多数抗炎作用归因于通过A(2A)腺苷受体(A(2A)AR)进行的信号传导。然而,此前已有研究表明,A(3)AR激动剂N(6)-(3-碘苄基)腺苷-5'-N-甲基甲酰胺(IB-MECA)能有效抑制从A(2A)AR“敲除”(A(2A)KO)小鼠获得的巨噬细胞释放TNF-α,这表明A(3)AR也可能调节细胞因子的表达。在此,我们证实A(2A)AR是抑制由Toll样受体依赖性(TLR)和TLR非依赖性刺激诱导的巯基乙酸盐激发的小鼠腹腔巨噬细胞释放TNF-α的主要AR亚型,但我们确定是A(2B)AR而非A(3)AR介导了腺苷的非A(2A)AR作用,因为1)从A(3)KO小鼠分离的巨噬细胞中,IB-MECA抑制TNF-α释放的能力未改变;2)A(2B)AR拮抗剂1,3-二丙基-8-[4-[((4-氰基苯基)氨基甲酰基甲基)氧基]苯基]黄嘌呤(MRS 1754)阻断了非选择性AR激动剂腺苷-5'-N-乙基甲酰胺(NECA)抑制从A(2A)KO小鼠分离的巨噬细胞释放TNF-α的能力。尽管A(2B)AR似乎能够抑制TNF-α释放,但A(2A)AR起主要抑制作用,因为MRS 1754并未阻断NECA抑制从野生型(WT)小鼠分离的巨噬细胞释放TNF-α的能力。此外,用MRS 1754阻断A(2B)ARs并不影响腺苷抑制WT巨噬细胞释放TNF-α的效力和效果。数据表明,腺苷主要通过A(2A)ARs抑制巨噬细胞释放TNF-α,尽管A(2B)AR似乎发挥潜在的抑制作用,在特定情况下可能有助于腺苷的抗炎作用。